protein TRAF6 (Cao et al., 1996) . How TRAF6 and other
We undertook a biochemical approach to filling in the gap between TRAF6 and IKK. Our approach begins with the establishment of a cell-free system that activates IKK in a NEMO-and TRAF6-dependent manner. Biochemical fractionation of the cell extract reveals two distinct factors that are required to activate IKK by TRAF6. We now report the purification and characterization of one of these factors, which turns out to be a dimeric ubiquitin-conjugating enzyme (E2) complex composed of Ubc13 and Uev1A (Mms2). This E2 complex was previously shown to catalyze the assembly of for Ub, which in this case positively regulates a protein kinase activity.
NF-B agonists trigger the phosphorylation of IB␣

Results
at both serines 32 and 36. To determine whether IB␣ is phosphorylated at these serine residues in the in vitro A Cell-Free System that Activates IKK TRAF6-inducible system, we tested in vitro translated, in Response to TRAF6 electrophoretic mobility shift (lane 2), mutation at both We sought to recapitulate the TRAF6-dependent activaserines 32 and 36 abolished this phosphorylation (lane tion of IKK in vitro in order to identify the missing link 8). Single point mutation at either S32 or S36 led to an between TRAF6 and IKK through biochemical fractionintermediary gel shift (lanes 4 and 6), which is indicative ation. As shown in Figure 1A , addition of recombinant of single site phosphorylation at the remaining wild-type TRAF6 to cell extracts prepared from 70Z pre-B cells serine residue. Therefore, the in vitro TRAF6-inducible led to the phosphorylation of endogenous IB␣ that system retains the specificity of IB␣ phosphorylation. could be detected with a phospho-IB␣-specific antibody (lane 2). This reaction is strictly dependent on NEMO, since cell extracts prepared from 1.3E2, a NEMO-defi- Figure 3C . This factor has an apparent molecular size of 35 kDa based on gel filtration chromatography (data not shown), and is separated into two bands on SDS-PAGE with molecular sizes of 16 and 19 kDa, respectively ( Figure 3B ). The intensity of these bands correlated with IKK-stimulatory activity, indicating that they are candidate subunits of TRIKA1 (␣ and ␤ subunits). The 16 and 19 kDa bands were excised for mass spectrometric analysis following digestion with trypsin. Peptide mass fingerprinting (MALDI-TOF) of the 16 kDa protein identified 9 peptides whose masses matched those predicted from human Ubc13, a Ub-conjugating enzyme ( Figure 3D ). The 19 kDa protein has 11 peptides whose masses matched those of an isoform of human Uev1 such as Uev1A ( Figure 3E ), a Ub-conjugating E2 enzyme variant (UEV) that is structurally related to E2 enzymes but lacks the catalytic cysteine residue found in a typical E2 (Rothofsky and Lin, 1997; Sancho et al., 1998).
Recombinant Ubc13/Uev1A Complex Supports the Activation of IKK by TRAF6
To verify that Ubc13 and Uev1A are indeed components of TRIKA1, we expressed these proteins in E. coli and whether other E2s could support TRAF6-mediated IKK activation ( Figure 4D ). Among several E2s tested, only Ubc13/Uev1A was capable of activating IKK together with TRAF6. These results confirm that Ubc13/Uev1A is for its activation. One of the candidate upstream activathe TRIKA1 that links TRAF6 to IKK activation. tors is TRAF6. However, unlike MEKK1, TRAF6 did not activate the purified IKK complex directly (Figure 2A , lanes 4 and 5). In contrast, the crude extract from 293 Ubc13/Uev1A Is Required for IKK Activation cells can be activated by TRAF6 (lane 2), suggesting by TRAF6 the existence of intermediary factors required for IKK The tight binding between Ubc13 and Uev1A makes it activation by TRAF6 in the extract. As an initial step to feasible to deplete endogenous Uev1A from crude cell identify these factors, we fractionated HeLa cytosolic extracts with immobilized GST-Ubc13, thus providing extract (S100) on Q-Sepharose through step elution with an opportunity to address the consequence of removing increasing concentration of NaCl ( Figure 2B ). SignifiUev1A. This is particularly useful in light of the fact that cantly, the activation of the IKK complex by TRAF6 rethe antibodies generated against Ubc13 or Uev1A fail quires at least two fractions, the unbound fraction (Fr.I) to immunoprecipitate the respective proteins, although and the 0.1-0.2 M NaCl eluate (Fr.IIa, lane 3). Omission they can detect the proteins by immunoblotting (data of either fraction abolishes IKK activation by TRAF6 not shown). As shown in Figure 5A , cell extracts were (lanes 4 and 5). The factor present in Fr.I is hereby redevoid of Uev1A after passage through GST-Ubc13-ferred to as TRAF6-Regulated IKK Activator 1 (TRIKA1), Sepharose (lane 2), whereas GST-Sepharose did not whereas the factor present in Fr.IIa is referred to as retain any Uev1A from the extracts (lanes 3 and 5). Con-TRIKA2.
sequently, cell extracts depleted of Uev1A are severely defective in IKK activation in the presence of TRAF6 ( Figure 5B , lane 7), whereas control extracts retain full Purification and Identification of TRAF6-Regulated IKK Activator 1 (TRIKA1) IKK activation potential (lanes 3 and 10). Addition of recombinant Ubc13/Uev1A to the Uev1A-depleted exWe have purified TRIKA1 from HeLa cytosolic extracts to apparent homogeneity through six steps of conventional tracts restored IKK activation in response to TRAF6 (lane 8). These results indicate that Ubc13/Uev1A is required chromatography ( Figure 3A) . Silver staining of fractions from the last MonoQ step is shown in Figure 3B , and for IKK activation by TRAF6 in vitro.
To determine whether Ubc13/Uev1A is required for the IKK stimulatory activity assay of the same fractions of a lysine at position 63 (K63) restored polyubiquitination (lane 10). These results show that TRAF6 facilitates the synthesis of polyUb chains through K63 rather than K48. In this regard, TRAF6 is a Ub ligase (E3) that partners with Ubc13/Uev1A (E2). We also found that TRAF2 functioned together with Ubc13/Uev1A to catalyze the synthesis of K63-linked polyUb chains (data not shown), consistent with the obligatory role of Ubc13/Uev1A in NF-B activation by TNF␣ and TRAF2 ( Figure 5C ). To determine whether the RING finger domain of TRAF6 is important for its Ub-conjugating activity, we mutated the highly conserved cysteine and histidine residues in the RING domain to generate two point mutants, C70A and C85A/H87A. These constructs were expressed in 293 cells as Flag-tagged proteins and immunopurified for ubiquitination assays ( Figure 6B ). While wild-type TRAF6 catalyzed the assembly of K63-linked polyUb chains from a K63 Ub mutant in the presence of E1 and Ubc13/Uev1A (lane 4), the RING finger mutations abolished this Ub-conjugating activity (lanes 6 and 8). These same mutations also abolished the ability of TRAF6 to activate the expression of an NF-B reporter gene (luciferase) when overexpressed ( Figure 6C ), suggesting that the NF-B-inducing activity of TRAF6 is linked to its Ub-conjugating activity through the use of the RING domain.
K63-Linked polyUb Chains Are Involved in IKK Activation by TRAF6
Our findings that TRAF6 and Ubc13/Uev1A are involved in IKK activation, and that they catalyze the synthesis of K63-linked polyUb chains, led us to investigate the role of these unique Ub chains in IKK activation. We first examined a panel of Ub mutants for their ability to activate IKK in vitro ( Figures 7A and 7B) . These mutants include a lysine-less mutant ( Figure 7B , lane 2, KO), single-lysine mutants, which contain one lysine with the remaining six lysine residues mutated to arginine (K6, K11, K27, K29, K33, K48, and K63; lanes 3-9), and single K/R mutants, which contain a single point mutation from lysine to arginine with the remaining lysines intact (R11, R29, R48, and R63; lanes 10-13). In addition, we also tested methylated Ub (MeUb, lane 1), in which all seven lysine residues were blocked by methylation, thus preventing elongation of Ub chains. Strikingly, MeUb, KO, and all single-lysine mutants except for K63 fail to support IKK activation by TRAF6 (lanes 1-9), indicating that K63 is the only important lysine on Ub required for this results further strengthen the conclusion that TRAF6-mediated activation of IKK requires the assembly of K63-linked polyUb chains.
The critical role of K63 rather than K48 of Ub in IKK activation raises the question of whether proteasomal degradation plays any role at all in IKK activation, since K48-linked polyUb chains are preferentially recognized by the proteasome (Chau et al., 1989) . In our in vitro reconstitution system, no proteasome was added to the assay, suggesting that IKK activation does not require proteasome. To rule out the possibility that any residual proteasomal activity might be required for IKK activation, we added proteasome inhibitors MG132 ( Figure  7D, lanes 4-6) or lactacystin (lanes 7-9) complex can no longer be activated directly by Ubc4/5, although it can be activated directly by MEKK1 (data not shown). Significantly, when the purified IKK complex had no effect on endogenous IB␣ phosphorylation stimulated by TRAF6 (lanes 3 and 6) . In contrast, Ub was supplemented with a fraction that is depleted of IKK, Ubc4/5-dependent activation of IKK was restored, mutants lacking any lysine (KO) or retaining only one lysine at position 48 (K48) exert a dominant-negative suggesting the existence of a factor required for IKK activation by Ubc4/5 (C. W. and Z. J. C., unpublished effect on endogenous IKK activation by TRAF6 (lanes 4 and 5). These mutants did not interfere with IKK activadata). This factor, which remains to be characterized, does not support the activation of IKK by Ubc13/Uev1A tion triggered by MEKK1 or IKK␤. Taken together, these and TRAF6. Conversely, Ubc4/5 cannot substitute for The mechanism by which p62 activates IKK in these pathways is not clear, but is thought to involve the bindUbc13/Uev1A in the activation of IKK by TRAF6 ( Figure  4D) , 1999) . Now that we show the IKK complex could be indepenlead to the identification of such a target. We have not detected ubiquitination of components of the IKK comdently activated by phosphorylation or by ubiquitination in vitro, which of these mechanisms might be responsiplex including NEMO, IKK␣, and IKK␤. However, some proteins known to participate in the NF-B pathway have ble for IKK activation in vivo? Strong support for IKK being activated by phosphorylation comes from the obbeen reported to undergo ubiquitination following engagement of ligands. For example, stimulation of cells servation that both IKK␣ and IKK␤ contain canonical MAPK phosphorylation sites, and that mutation of these with TNF␣ led to "some kind of covalent modification" of the protein kinase RIP that resembles ubiquitination sites significantly interferes with IKK activation in response to various stimuli (Mercurio et al., 1997). This (Zhang et al., 2000) . The conjugated form of RIP appears within one minute of TNF␣ treatment, and then decays and other experiments led to the idea that there is an upstream kinase (IKKK) that phosphorylates IKK and is with kinetics that coincides with transient activation of IKK. Interestingly, there is no apparent degradation of responsible for its activation. In fact, the in vitro TRAF6-inducible system we set up was initially designed to RIP throughout the time course when IB␣ is rapidly degraded. It remains to be determined whether this form identify a putative IKKK downstream of TRAF6. However, upon fractionation, it became clear that the factors of RIP modification is related to IKK activation. Recently, a protein associated with atypical PKCs called p62 has mediating IKK activation in response to TRAF6 were ubiquitination enzymes. We had also attempted to idenbeen shown to be involved in IKK activation in both the TNF and IL-1 signaling pathways (Sanz et al., 2000) .
tify an IKKK through fractionation of TNF␣-stimulated Cell 88, 213-222.
